- Trials with a EudraCT protocol (184)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
184 result(s) found for: Peripheral blood mononuclear cells.
Displaying page 1 of 10.
EudraCT Number: 2011-002928-41 | Sponsor Protocol Number: Immunity_TBE | Start Date*: 2013-01-14 |
Sponsor Name:Med. Uni. Wien, Klinik für Innere I | ||
Full Title: Characterization of humoral and cellular immunity for tick-borne encephalitis (TBE) vaccination in allogeneic blood and marrow graft recipients: a pilot study | ||
Medical condition: Characterization of humoral and cellular immunity for tick-borne encephalitis (TBE) vaccination in allogeneic blood and marrow graft recipients: a pilot study Study group consists of patients 11... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-000633-39 | Sponsor Protocol Number: FEC-TH | Start Date*: 2012-05-21 |
Sponsor Name:Fundación para la Formación e Investigación Sanitaria | ||
Full Title: Extracorporeal photopheresis in liver transplantation. Clinical trial phase I/II safety and efficacy in patients with progressive withdrawal of immunosuppression. | ||
Medical condition: Liver transplantation more than 2 years of evolution to complications of immunosuppression. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-001391-42 | Sponsor Protocol Number: Speed-Covid | Start Date*: 2021-05-12 |
Sponsor Name:Medical University of Graz | ||
Full Title: Characterisation of the effects of Spermidine on the immune response to Covid-19 vaccine in older people - a feasibility study | ||
Medical condition: For assessing the immune cell function after COVID-19 vaccine, peripheral blood mononuclear cells (PBMC) will be separated after blood sampling and measurements as follows will be done: • FACS anal... | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2018-000112-21 | Sponsor Protocol Number: MESI-STRAT-WOO | Start Date*: 2018-09-03 | |||||||||||
Sponsor Name:Ruprecht-Karls-Universität Heidelberg, Medizinische Fakultät, vertreten durch das Universitätsklinikum Heidelberg | |||||||||||||
Full Title: Prospective Window of opportunity trial 3 weeks neoadjuvant Anastrozole in Postmenopausal Women with Estrogen receptor positive (ER+) Breast Cancer | |||||||||||||
Medical condition: (ER+) Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003960-22 | Sponsor Protocol Number: WOO2 | Start Date*: 2021-03-15 | |||||||||||
Sponsor Name:Medical University of Innsbruck | |||||||||||||
Full Title: Prospective Window of opportunity trial of 3 weeks neoadjuvant Anastrozole in Postmenopausal Women with Estrogen receptor positive (ER+) Breast Cancer | |||||||||||||
Medical condition: (ER+) Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001653-27 | Sponsor Protocol Number: MarsyasII | Start Date*: 2019-12-20 | |||||||||||
Sponsor Name:Aposcience AG | |||||||||||||
Full Title: A randomized, placebo-controlled, double-blind study to evaluate safety and dose dependent clinical efficacy of APO-2 at three different doses in patients with diabetic foot ulcer (MARSYAS II) | |||||||||||||
Medical condition: Diabetic Foot Ulcer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) CZ (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001772-20 | Sponsor Protocol Number: CMR001/05 | Start Date*: 2007-03-15 |
Sponsor Name:Clinica Rotger | ||
Full Title: Effect of intracoronary injection of autologous stemm cells on left ventricular ejection fraction and volumes one year after an acute myocardial infarction. Efecto de la inyección intracoronaria d... | ||
Medical condition: The trial evaluates the effect on left ventricular function recovery of the intracoronary injection of mononuclear white cells obtained from peripheral blood in the week after an acute myocardial i... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-006227-31 | Sponsor Protocol Number: 0881X1-4503 | Start Date*: 2009-01-09 |
Sponsor Name:Medical Faculty, Otto-von-Guericke-University Magdeburg | ||
Full Title: Inflammatory Topoproteome of Psoriasis under Etanercept Treatment | ||
Medical condition: Patients with a severe psoriasis will be treated with Enbrel (Etanercept) 2 x 50 mg s.c. per week over 12 weeks (n = 6 patients). The treatment follows rigorously the approved label of the drug. Th... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-003594-95 | Sponsor Protocol Number: MTXSB2018 | Start Date*: 2019-04-30 | ||||||||||||||||
Sponsor Name:Amsterdam UMC location AMC | ||||||||||||||||||
Full Title: Methotrexate to suppress immunogenicity to anti-tumor necrosis factor therapy in IBD patients with loss of response | ||||||||||||||||||
Medical condition: Inflammatory bowel disease: Crohn's disease and Ulcerative colitis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001971-61 | Sponsor Protocol Number: SALYCENDO | Start Date*: 2016-08-29 |
Sponsor Name:Radboudumc | ||
Full Title: The effects of acetylsalicylic acid on immunoparalysis following human endotoxemia. | ||
Medical condition: We will investigate the effects of acetylsalicylic acid on immunoparalysis following human endotoxemia in healthy male volunteers | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-000580-24 | Sponsor Protocol Number: | Start Date*: 2019-05-17 |
Sponsor Name:Hull & East Yorkshire Hospitals NHS trust | ||
Full Title: A single arm, open-label clinical trial of azithromycin in pulmonary sarcoidosis | ||
Medical condition: Sarcoidosis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2006-003384-30 | Sponsor Protocol Number: IR902-231 | Start Date*: 2007-02-26 |
Sponsor Name:The Immune Response Corporation | ||
Full Title: A Phase II Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for Multiple Sclerosis | ||
Medical condition: Multiple Sclerosis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-001371-69 | Sponsor Protocol Number: EVITAs | Start Date*: 2016-09-30 |
Sponsor Name:Fundació Lluita contra la SIDA | ||
Full Title: Tenofovir DP concentrations in seminal cells and semen quality in HIV-1 infected patients receiving a TAF containing regimen | ||
Medical condition: HIV-1 positive patients | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-003142-27 | Sponsor Protocol Number: RALAM | Start Date*: 2015-07-13 |
Sponsor Name:Fundació Clinic per a la Recerca Biomédica | ||
Full Title: A pilot 24-week open-label, randomized, controlled clinical trial to assess the safety, tolerability and efficacy of dual therapy with Raltegravir/Lamivudine combination when replacing standard com... | ||
Medical condition: Chronic HIV infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-000986-60 | Sponsor Protocol Number: RALAM-Roll-Over | Start Date*: 2017-10-11 | |||||||||||
Sponsor Name:Fundació Clinic per a la Recerca Biomédica | |||||||||||||
Full Title: Phase 3b, single arm, single site simplification study of HIV-1 infected patients with virological suppression under the combination of 3TC (150 mg BID) plus Raltegravir (400 mg BID) switching to 3... | |||||||||||||
Medical condition: Patients of RALAM study (NCT02284035) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006922-32 | Sponsor Protocol Number: HOADO | Start Date*: 2009-02-09 | |||||||||||
Sponsor Name:RUNMC | |||||||||||||
Full Title: Heme oxygenase (HO) activity in humans. Effects of heme arginate (Normosang®) on parameters of HO activity and on adenosine induced vasodilation. | |||||||||||||
Medical condition: Normosang treatment will be used to evaluate heme oxygenase induction in healthy subjects. Results will be used for future studies concerning diabetes related cardiovascular disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021435-14 | Sponsor Protocol Number: n.a. | Start Date*: 2010-12-06 |
Sponsor Name:Academisch Medisch Centrum Amsterdam | ||
Full Title: Effects of abatacept (Orencia®) on biomarkers in synovial tissue in patients with rheumatoid arthritis | ||
Medical condition: rheumatoid arthritis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2009-013284-19 | Sponsor Protocol Number: HINABS-ITI | Start Date*: 2009-12-10 |
Sponsor Name:Medical University Innsbruck | ||
Full Title: Immune tolerance induction in MS patients with neutralizing antibodies against interferon-beta | ||
Medical condition: multiple sclerosis patients with neutralizing antibodies against interferon-beta | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-011152-22 | Sponsor Protocol Number: GTG003.08 | Start Date*: Information not available in EudraCT |
Sponsor Name:GENETHON | ||
Full Title: Phase 1/2 clinical trial of haematopoietic stem cell gene therapy for the Wiskott-Aldrich Syndrome | ||
Medical condition: Phase 1/2 clinical trial of haematopoietic stem cell gene therapy for the Wiskott-Aldrich Syndrome. An open labelled, non-randomised, phase I/II, cohort study involving a single infusion of autolo... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male | |
Trial protocol: FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-001833-38 | Sponsor Protocol Number: 77347 | Start Date*: 2023-04-20 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: The Dutch Parkinson GBA Ambroxol trial (DUPARG-AMBROXOL): A randomised, double-blind, placebo-controlled, single-center trial with Ambroxol in Parkinson patients with a GBA mutation. | ||
Medical condition: Parkinson's disease with a GBA1 mutation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
